Apimeds Pharmaceuticals US, Inc.
APUS
$2.20
-$1.80-45.00%
AMEX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 275.60K | 300.00K | 427.80K | 271.70K | 530.50K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 275.60K | 300.00K | 427.80K | 271.70K | 559.10K |
| Operating Income | -275.60K | -300.00K | -427.80K | -271.70K | -559.10K |
| Income Before Tax | -311.60K | -332.50K | -449.40K | -296.50K | -567.00K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -311.60K | -332.50K | -449.40K | -296.50K | -567.00K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -311.60K | -332.50K | -449.40K | -296.50K | -567.00K |
| EBIT | -275.60K | -300.00K | -427.80K | -271.70K | -559.10K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.04 | -0.04 | -0.06 | -0.04 | -0.09 |
| Normalized Basic EPS | -0.02 | -0.03 | -0.04 | -0.02 | -0.06 |
| EPS Diluted | -0.04 | -0.04 | -0.06 | -0.04 | -0.09 |
| Normalized Diluted EPS | -0.02 | -0.03 | -0.04 | -0.02 | -0.06 |
| Average Basic Shares Outstanding | 7.90M | 7.90M | 7.90M | 7.90M | 6.37M |
| Average Diluted Shares Outstanding | 7.90M | 7.90M | 7.90M | 7.90M | 6.37M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |